Remepy has announced a collaboration with Merck KGaA to develop Hybrid Drugs, a new class of medication combining pharmacological treatments with personalized digital therapeutic protocols via a mobile app. The partnership will initially focus on rare tumor treatments in the U.S., with potential expansion into other therapeutic areas. Hybrid Drugs aim to enhance clinical outcomes by integrating medication with evidence-based behavioral and cognitive interventions. Recent advancements in regulatory frameworks are creating opportunities for the integration of digital health solutions into traditional pharmaceutical practices.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://finance.yahoo.com/sectors/healthcare/articles/remepy-announces-collaboration-merck-kgaa-110000110.html
